Sanofi (SNY) Shares Sold by American Century Companies Inc.
American Century Companies Inc. lessened its holdings in Sanofi (NYSE:SNY) by 37.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,289 shares of the company’s stock after selling 6,633 shares during the period. American Century Companies Inc.’s holdings in Sanofi were worth $541,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Point View Wealth Management Inc. raised its stake in Sanofi by 6.1% in the 2nd quarter. Point View Wealth Management Inc. now owns 17,974 shares of the company’s stock valued at $861,000 after acquiring an additional 1,031 shares during the period. ProVise Management Group LLC raised its stake in Sanofi by 62.5% in the 2nd quarter. ProVise Management Group LLC now owns 130,513 shares of the company’s stock valued at $6,253,000 after acquiring an additional 50,175 shares during the period. MAI Capital Management bought a new stake in Sanofi in the 2nd quarter valued at $214,000. BB&T Securities LLC raised its stake in Sanofi by 3.8% in the 2nd quarter. BB&T Securities LLC now owns 359,471 shares of the company’s stock valued at $17,222,000 after acquiring an additional 13,059 shares during the period. Finally, Blair William & Co. IL raised its stake in Sanofi by 42.7% in the 2nd quarter. Blair William & Co. IL now owns 18,824 shares of the company’s stock valued at $902,000 after acquiring an additional 5,635 shares during the period. Institutional investors and hedge funds own 9.33% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Sanofi (SNY) Shares Sold by American Century Companies Inc.” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/19/sanofi-sny-shares-sold-by-american-century-companies-inc.html.
Sanofi (NYSE:SNY) opened at 48.64 on Tuesday. Sanofi has a one year low of $36.81 and a one year high of $50.24. The firm has a 50-day moving average price of $48.33 and a 200-day moving average price of $47.42. The firm has a market capitalization of $122.16 billion, a price-to-earnings ratio of 11.34 and a beta of 0.88.
Sanofi (NYSE:SNY) last issued its earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. The firm had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The firm’s revenue was down 2.3% on a year-over-year basis. Analysts expect that Sanofi will post $3.34 EPS for the current year.
In other news, major shareholder Sanofi bought 60,595 shares of the stock in a transaction on Wednesday, August 23rd. The shares were purchased at an average cost of $478.98 per share, for a total transaction of $29,023,793.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.00% of the company’s stock.
A number of research firms recently weighed in on SNY. BidaskClub cut Sanofi from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Argus increased their price target on Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, June 9th. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Friday, June 2nd. HSBC Holdings plc upgraded Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a research note on Friday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company’s stock. Sanofi presently has a consensus rating of “Hold” and an average target price of $54.00.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.